HK1222655A1 - -{ }- -{ -嗎啉基甲基 -吡咯- -基 亞甲基}- -氧代- -二氫- -吲哚- -基 甲基 -噻唑烷- -二酮的新型鹽、其製備以及包含其的製劑 - Google Patents

-{ }- -{ -嗎啉基甲基 -吡咯- -基 亞甲基}- -氧代- -二氫- -吲哚- -基 甲基 -噻唑烷- -二酮的新型鹽、其製備以及包含其的製劑

Info

Publication number
HK1222655A1
HK1222655A1 HK16110825.2A HK16110825A HK1222655A1 HK 1222655 A1 HK1222655 A1 HK 1222655A1 HK 16110825 A HK16110825 A HK 16110825A HK 1222655 A1 HK1222655 A1 HK 1222655A1
Authority
HK
Hong Kong
Prior art keywords
morpholinylmethyl
thiazolidine
pyrrol
indol
dione
Prior art date
Application number
HK16110825.2A
Other languages
English (en)
Inventor
Flohic Alexandre Le
Jrme Guidotti
Philippe Letellier
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of HK1222655A1 publication Critical patent/HK1222655A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
HK16110825.2A 2013-07-12 2016-09-13 -{ }- -{ -嗎啉基甲基 -吡咯- -基 亞甲基}- -氧代- -二氫- -吲哚- -基 甲基 -噻唑烷- -二酮的新型鹽、其製備以及包含其的製劑 HK1222655A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1356870A FR3008411B1 (fr) 2013-07-12 2013-07-12 Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent
PCT/FR2014/051783 WO2015004395A1 (fr) 2013-07-12 2014-07-11 Nouveau sel de la 3-[(3-{[4-(4-morpholinylméthyl)-1h-pyrrol-2-yl]méthylène}-2-oxo-2,3-dihydro-1h-indol-5-yl)méthyl]-1,3-thiazolidine-2,4-dione, sa préparation, et les formulations qui le contiennent

Publications (1)

Publication Number Publication Date
HK1222655A1 true HK1222655A1 (zh) 2017-07-07

Family

ID=50424327

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16110306.0A HK1222172A1 (zh) 2013-07-12 2016-08-30 -{ }- -{ -嗎啉基甲基 -吡咯- -基 亞甲基}- -氧代- -二氫- -吲哚- -基 甲基 -噻唑烷- -二酮的新型鹽、其製備以及包含其的製劑
HK16110825.2A HK1222655A1 (zh) 2013-07-12 2016-09-13 -{ }- -{ -嗎啉基甲基 -吡咯- -基 亞甲基}- -氧代- -二氫- -吲哚- -基 甲基 -噻唑烷- -二酮的新型鹽、其製備以及包含其的製劑

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK16110306.0A HK1222172A1 (zh) 2013-07-12 2016-08-30 -{ }- -{ -嗎啉基甲基 -吡咯- -基 亞甲基}- -氧代- -二氫- -吲哚- -基 甲基 -噻唑烷- -二酮的新型鹽、其製備以及包含其的製劑

Country Status (47)

Country Link
US (2) US9925195B2 (zh)
EP (1) EP3019497B1 (zh)
JP (1) JP6532459B2 (zh)
KR (2) KR20160030399A (zh)
CN (1) CN105377843B (zh)
AP (1) AP2016008976A0 (zh)
AR (1) AR096882A1 (zh)
AU (1) AU2014289059B2 (zh)
CA (1) CA2916380C (zh)
CL (1) CL2016000013A1 (zh)
CR (1) CR20160012A (zh)
CU (1) CU20160005A7 (zh)
CY (1) CY1119259T1 (zh)
DK (1) DK3019497T3 (zh)
DO (1) DOP2016000005A (zh)
EA (1) EA031526B1 (zh)
ES (1) ES2632570T3 (zh)
FR (1) FR3008411B1 (zh)
GE (1) GEP201706712B (zh)
GT (1) GT201600004A (zh)
HK (2) HK1222172A1 (zh)
HR (1) HRP20171060T1 (zh)
HU (1) HUE032568T2 (zh)
IL (1) IL243526B (zh)
JO (1) JO3292B1 (zh)
LT (1) LT3019497T (zh)
MA (1) MA38759B1 (zh)
MD (1) MD4507C1 (zh)
ME (1) ME02735B (zh)
MX (1) MX360291B (zh)
MY (1) MY183197A (zh)
NI (1) NI201600009A (zh)
NZ (1) NZ715841A (zh)
PE (1) PE20160079A1 (zh)
PH (1) PH12016500017A1 (zh)
PL (1) PL3019497T3 (zh)
PT (1) PT3019497T (zh)
RS (1) RS55945B1 (zh)
RU (1) RU2680826C9 (zh)
SA (1) SA516370388B1 (zh)
SG (1) SG11201510570YA (zh)
SI (1) SI3019497T1 (zh)
TN (1) TN2015000566A1 (zh)
TW (2) TW201630906A (zh)
UA (1) UA114041C2 (zh)
UY (1) UY35629A (zh)
WO (1) WO2015004395A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10245270B2 (en) * 2013-07-12 2019-04-02 Les Laboratoires Servier Salt of 3-[(3-{[4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1H-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, its preparation, and formulations containing it
FR3039401B1 (fr) * 2015-07-31 2018-07-13 Les Laboratoires Servier Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ520640A (en) * 2000-02-15 2005-04-29 Upjohn Co Pyrrole substituted 2-indolinone protein kinase inhibitors
WO2002032861A2 (en) * 2000-10-17 2002-04-25 Merck & Co., Inc. Orally active salts with tyrosine kinase activity
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
RU2316554C2 (ru) * 2001-12-27 2008-02-10 Тереванс, Инк. Производные индолина, используемые как ингибиторы протеинкиназы
WO2005040116A2 (en) * 2003-10-24 2005-05-06 Schering Aktiengesellschaft Indolinone derivatives and their use in treating disease-states such as cancer
KR101396639B1 (ko) * 2005-12-05 2014-05-21 제노포트 인코포레이티드 레보도파 프로드럭 메실레이트, 그것의 조성물 및 그것의용도
FR2948940B1 (fr) * 2009-08-04 2011-07-22 Servier Lab Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
JP2016523953A (ja) 2016-08-12
CY1119259T1 (el) 2018-02-14
FR3008411A1 (fr) 2015-01-16
RU2680826C2 (ru) 2019-02-28
SA516370388B1 (ar) 2017-12-14
SI3019497T1 (sl) 2017-07-31
PL3019497T3 (pl) 2017-09-29
EP3019497B1 (fr) 2017-04-12
SG11201510570YA (en) 2016-01-28
RU2680826C9 (ru) 2019-03-01
ME02735B (me) 2017-10-20
CN105377843B (zh) 2019-03-05
JP6532459B2 (ja) 2019-06-19
HRP20171060T1 (hr) 2017-10-06
CN105377843A (zh) 2016-03-02
AU2014289059A1 (en) 2016-02-04
EA201600101A1 (ru) 2016-06-30
TW201504236A (zh) 2015-02-01
DOP2016000005A (es) 2016-12-15
CL2016000013A1 (es) 2016-08-12
KR20180028554A (ko) 2018-03-16
MY183197A (en) 2021-02-18
LT3019497T (lt) 2017-05-25
HUE032568T2 (hu) 2017-09-28
PH12016500017B1 (en) 2016-04-18
KR20160030399A (ko) 2016-03-17
TN2015000566A1 (fr) 2017-04-06
NZ715841A (en) 2019-04-26
TW201630906A (zh) 2016-09-01
UY35629A (es) 2015-01-30
FR3008411B1 (fr) 2015-07-03
MD4507C1 (ro) 2018-03-31
DK3019497T3 (en) 2017-08-07
RS55945B1 (sr) 2017-09-29
CR20160012A (es) 2016-02-08
EA031526B1 (ru) 2019-01-31
IL243526B (en) 2019-09-26
MX2016000332A (es) 2016-05-09
MD4507B1 (ro) 2017-08-31
MA38759B1 (fr) 2018-09-28
EP3019497A1 (fr) 2016-05-18
US20180207171A1 (en) 2018-07-26
IL243526A0 (en) 2016-02-29
GT201600004A (es) 2018-09-28
UA114041C2 (xx) 2017-04-10
RU2016104642A (ru) 2017-08-17
NI201600009A (es) 2016-02-11
MX360291B (es) 2018-10-29
CU20160005A7 (es) 2016-05-30
PH12016500017A1 (en) 2016-04-18
AR096882A1 (es) 2016-02-03
CA2916380A1 (fr) 2015-01-15
HK1222172A1 (zh) 2017-06-23
ES2632570T3 (es) 2017-09-14
TWI554510B (zh) 2016-10-21
US9925195B2 (en) 2018-03-27
JO3292B1 (ar) 2018-09-16
US20160151378A1 (en) 2016-06-02
GEP201706712B (en) 2017-07-25
AU2014289059B2 (en) 2017-05-25
PT3019497T (pt) 2017-05-15
CA2916380C (fr) 2017-11-21
MA38759A1 (fr) 2018-01-31
WO2015004395A1 (fr) 2015-01-15
AP2016008976A0 (en) 2016-01-31
PE20160079A1 (es) 2016-02-06
MD20160003A2 (ro) 2016-06-30

Similar Documents

Publication Publication Date Title
EP2877472A4 (en) Novel heterocyclic heteroaryl compounds, composition and method therefor
IL259824B (en) History of 2-[3-(azolyl)phenyl]-3,1-thiazole-5-carboxylic acid for use as drugs
EP3376866A4 (en) 4 - ((6-2- (2,4-DIFLUOROPHENYL) -1,1-DIFLUORO-2-YL) PROPYL) PYRIDIN-3-YL) OXY) BENZONITRILE AND METHODS FOR PREPARING THE SAME
HUE051634T2 (hu) 5-[2-(Piridin-2-il-amino)-1,3-tiazol-5-il]-2,3-dihidro-1H-izoindol-1-on-származékok és alkalmazásuk delta és gamma foszfatidilinozit-3-kináz duális inhibitoraiként
EP2970167A4 (en) SOLID FORMS OF 5- (HALOMETHYL) FURFURAL AND PROCESS FOR THE PREPARATION THEREOF
HK1222655A1 (zh) -{ }- -{ -嗎啉基甲基 -吡咯- -基 亞甲基}- -氧代- -二氫- -吲哚- -基 甲基 -噻唑烷- -二酮的新型鹽、其製備以及包含其的製劑
HK1221219A1 (zh) -二氟苯基 -甲基- -氧吡啶- -基 甲基 咪唑烷- -二酮及含有該化合物的藥物
EP3013333A4 (en) Heterocyclic compounds and methods of use thereof for the treatment of hepatitis c
TH1601000138A (th) เกลือชนิดใหม่ของ 3-[(3-{[4-(4-มอร์โฟลินิลเมทธิล)-1h-ไพร์รอล-2-อิล]เมทธิลลีน}-2-ออกโซ-2,3-ไดไฮโดร-1h-อินดอล-5-อิล)เมทธิล]-1,3-ไธอะโซลิดีน-2,4-ไดโอน การเตรียมของมันและสูตรผสมที่มีมันประกอบอยู่
PT3124025T (pt) Combinação entre 3-[(3-{[4-(4-morfolinilmetil)-1h-pirrol-2-il]-metileno}-2-oxo-2,3-di-hidro-1h-indol-5-il)metil]-1,3-tiazolidino-2,4-diona e um inibidor de tir-cinase do rfce
IL224486B (en) History of 2-phenyl-1-[4-(2-thiazolyl)-1-piperidinyl]ethanone as a fungicide

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210710